TME Pharma Announces Oral Presentation at Esmo Congress 2024 with Updated Results from Nox-A12 Gloria Phase 1/2 Trial in Glioblastoma
Presentation highlights data from the combined inhibition of angiogenesis and vasculogenesis with NOX-A12 and bevacizuma…